American College of Cardiology (ACC) Clinical Collection on Cardiomyopathies

A course of five teaching modules that contains scientific reviews in e-learning format. You will have access to the latest developments in the care of patients with cardiomyopathies, both in the study of the disease and in the management of patients in their clinical practice.

By completing the course you will be able to obtain course credits from the National Health System.

Dates: 11/10/2024 – 10/10/2025
X,X credits (38 teaching hours)
Credits have been requested from the National Health System.
Registration number: 09/038204-MD

Lesson 1: Cardiomyopathies (excluding hypertrophic), generalities (7h teaching hours)

• Cardiomyopathies
• Cardiomyopathies 1: Non ischemic Genetic and ARVC (Video 23:00)
• Cardiomyopathies 2: Cardiac sarcoidosis (Video 15:00)
• Echocardiographic Assessment of Cardiomyopathies - Case Study 1 and 2

Lesson 2: Hypertrophic cardiomyopathies, general (7h teaching hours)

• Hypertrophic Cardiomyopathy (HF SAP + ACCSAP + Video 25:00)
• The five important things to know about HCM (podcast 13:53)

Lesson 3: Diagnostic Imaging (Echocardiography, Magnetic Resonance Imaging) (6h teaching hours)

• ​​​Echocardiographic Assessment of Cardiomyopathies Part 2: Hypertrophic Cardiomyopathy and Restrictive Cardiomyopathies
• Challenging Clinical Cases in Cardiac Amyloidosis
• PYP Imaging for Diagnosing Cardiac Amyloidosis
• Echocardiographic Assessment of Cardiomyopathy

Lesson 4: Comparative analysis of Guidelines (ACC, ESC and SEC) (10h teaching hours)

• 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary
• 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
• Directrices de 2020 para el diagnóstico y el tratamiento de pacientes con miocardiopatía hipertrófica
• Applying Shared Decision Making to Sports Participation for a Patient With Hypertrophic Cardiomyopathy
• Hypertrophic Cardiomyopathy in Adolescence: Application of Guidelines 

Lesson 5: Management and treatment of cardiomyopathies (6h teaching hours)

• Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
• Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
• Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy
• The Patient's Voice | HCM: Understandingthe Patient Journey From Diagnosis toTreatment
• Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy - VALOR-HCM

Lección 6: ACC Anywhere. Focus on HMC

• Revolutionizing HCM Care: The Role of Cardiac Myosin Inhibitors 
• Cardiac Myosin Inhibitors in HCM: Dawn of a New Era in Precision Medicine
• Medical Management and Risk Stratification of HCM in 2024
• The Evolving Role of Multimodality Imaging in HCM
• Contemporary Genetics and Risk Stratification in HCM